The life expectancy for pancreatic cancer patients has seen no substantial changes in the last 40 years as very few and mostly just palliative treatments are available. As the five years survival rate remains around 5%, the identification of novel pharmacological targets and development of new therapeutic strategies are urgently needed. Here we demonstrate that inhibition of the G protein-coupled receptor GPR55, using genetic and pharmacological approaches, reduces pancreatic cancer cell growth in vitro and in vivo and we propose that this may represent a novel strategy to inhibit pancreatic ductal adenocarcinoma (PDAC) progression. Specifically, we show that genetic ablation of Gpr55 in the KRAS WT/G12D /TP53
Introduction
The progression from normal duct epithelium to infiltrating pancreatic ductal adenocarcinoma (PDAC) involves development of a characteristic pattern of precursors named pancreatic intraepithelial neoplasias (PanIN), histologically classified into distinct stages (PanIN 1a, PanIN 1b, PanIN 2, and PanIN 3) which eventually develop into PDAC, further classified in five distinct stages [1] . The genetic alterations associated with this process have been extensively characterised and they involve activating mutations of oncogenes, inactivating mutations of tumour suppressors as well as increased copy numbers of receptors [2] . For instance it is now well established that activating mutations of the oncogene KRas occur early during PanINs development and are detected in 85-90% of PDAC tumours [3] . On the other hand inactivating mutations of the tumour suppressor TP53 occur in 70% of the latest stages of PanIN progression [4] . Transgenic mouse models have shed much light into the role of these specific mutations during PDAC development. The KRAS WT/G12D /Pdx1-Cre +/+ (KC) model which expresses a constitutively active KRas selectively in the pancreas is able to reproduce the PanIN lineage with a 100% penetrance but only few mice actually develop PDAC [5] . On the contrary, the transgenic KRAS WT/G12D /TP53
WT/R172H /Pdx1-Cre
(KPC) mice which additionally bear the TP53 inactivating mutation develop the full PanIN range and PDAC with pathology very similar to human PDAC [6] . Therefore these transgenic models point to a key role for activated KRas in the early stage of neoplasias/cancer development and a central role for loss/inactivation of p53 in driving progression from the final PanINs stages to full PDAC. In the last years our understanding of the genetic causes of PDAC has greatly increased but sadly this has not resulted in significant improvement of treatment options for patients. Surgical resection can lead to long-term survival and provides effective palliation but it is only applicable to patients with stage I and II PDAC. Chemotherapy and radiation therapy following the resection reduce metastatic development but these treatments result in little improvement of patient survival. Until very recently, Gemcitabine (GEM) was the only FDA-approved treatment for primary PDAC, but in most cases it can only prolong survival by several weeks [7] . Some combinations of drugs have proven slightly more successful although they still effectively increase patients' survival by merely 2-4 months compared to GEM treatment [8, 9] . Several clinical trials are ongoing but currently PDAC remains one of the most aggressive cancers with a one year survival rate of 19% and five years survival rate of 5% [10] . Identification of novel pharmacological targets and development of new therapeutic strategies are urgently needed [11] .
Here we investigated the therapeutic potential of targeting the G protein-coupled receptor GPR55 in PDAC. GPR55 was identified as the receptor for the phospholipid lysophosphatidylinositol (LPI) [12] . Increasing evidence now suggests that GPR55 plays an important role in many cancer types [11] . Whether targeting the receptor could ultimately result in improvement of survival and whether this strategy could represent a genuine novel therapeutic approach remains to be determined. Indeed, no study so far has investigated whether inhibition of GPR55 could improve survival of transgenic models that closely mirror the human disease.
Using genetic and pharmacological approaches we demonstrate that GPR55 has a central role in PDAC progression driven by TP53 mutations. Furthermore, we show that inhibition of this receptor, especially in combination with GEM, reduces cancer progression and significantly improves survival in a transgenic mouse model of PDAC. These data provide the first evidence that inhibition of GPR55 represents a novel therapeutic strategy which can counteract PDAC progression and improve survival rate.
Results
Genetic disruption of Gpr55 inhibits pancreatic cancer proliferation in vivo and it improves survival in a PDAC mouse model
Immunohistochemistry (IHC) analysis of human normal pancreatic and PDAC specimens showed that GPR55 immunoreactivity was confined to the islets of Langerhans (Fig. 1a) in normal pancreatic tissues, as previously reported [13] , while acinar cells and ducts were consistently negative (Fig. 1a) . On the other hand, GPR55 was expressed in 14 out of 54 human PDAC specimens (25.9%), indicating an accumulation of GPR55 in cancer tissues. Consistently, GPR55 was detected in PDAC specimens derived from implantation of patient-derived pancreatic cancer cells (patient-derived xenografts, PDX, Fig. 1a ) and in a panel of PDAC cell lines (Supplementary Figure 1a) .
To determine the role of GPR55 in PDAC, KPC mice were crossed with mice harbouring homozygous deletion of Gpr55 (GPR55 −/− ) [14] to obtain the "KPCG" strain.
Consistent with results from human tissues, IHC analysis indicated that GPR55 was specifically expressed by cells of the islets of Langerhans in Pdx1-Cre +/+ and KPC mice, but not in KPCG mice (Supplementary Figure 1b) . Moreover, expression of GPR55 was detected in PDAC cells from KPC but not KPCG mice (Supplementary Figure 1b) , confirming the specificity of the anti-GPR55 antibody. Strikingly, genetic disruption of Gpr55 significantly improved survival (Fig. 1b) . Specifically, the median survival was 32.5 days longer in KPCG mice (n = 18) than in KPC mice (n = 21). IHC analysis of corresponding dissected tumours indicated that GPR55 disruption reduced expression of the proliferative index Ki67 in the epithelial cells, specifically during the PanIN 2 and PanIN 3 progression stages (Fig. 1c) , indicating a role for GPR55 in pancreatic cancer cell proliferation. These data demonstrate that GPR55 is crucial for PDAC development and/or progression in vivo. Figures 2a and c and e) and anchorage-independent growth (Fig. 2a, b) . Efficient downregulation of GPR55 was confirmed by RTqPCR ( Supplementary Figures 2b and d and f) . The inhibition of cell growth was mainly due to an effect on cell cycle progression as GPR55 downregulation significantly blocked the cell cycle at the G1/S transition phase (Supplementary Figures 3a and b) and reduced the mRNA levels of cyclins involved in regulation of the G1/S transition phase (including cyclin D1 and cyclin D2) without affecting mRNA levels of cyclin B1, which is involved in the G2/M transition (Supplementary Figure 3c) . No increase in apoptosis was detected in PDAC cells upon GPR55 downregulation as assessed by Caspase 3 activity (Supplementary Figure 3d ) or Annexin V/FACS ( Supplementary  Figure 3e) assays. These data demonstrate that GPR55 plays a specific role in PDAC cell proliferation/growth.
To further investigate the mechanism involved in cell growth and cell cycle regulation, the signalling pathways downstream of GPR55 were investigated in PDAC cells. As shown in Supplementary Figure 3f , phosphorylation of ERK1/2 at residues Threonine 202 and Tyrosine 204 was reduced in HPAFII cells transiently transfected with specific siRNAs targeting GPR55 compared to cells transfected with a non-targeting siRNA ("siControl") or incubated with transfection reagent alone ("untreated"). GPR55 downregulation further inhibited phosphorylation of S6 at its residues Serine 235/236 (Supplementary Figure 3f) , which can be regulated downstream of the MAPK/ERK signalling pathway [15] . Efficient downregulation of GPR55 was confirmed by Western blot (Supplementary Figure 3f) . No effect on the total levels of ERK and S6 was detected upon downregulation of GPR55 (Supplementary Figure 3f) . Consistently, IHC analysis revealed a decrease in both ERK1/2 and S6 phosphorylation in tumour specimens from KPCG mice compared to KPC mice (Fig. 2c, d ).
These data indicate that one of the mechanisms by which GPR55 controls pancreatic cancer cell growth may be through regulation of the MAPK/ERK signalling pathway.
p53 regulates GPR55 protein expression through modulation of miR34b-3p levels
To assess further the specific role of GPR55 during PDAC development/progression we crossed GPR55 −/− mice with KC mice, which do not harbor the TP53 mutation. No statistical differences were found in the survival of KC (n = 19) compared to GPR55 −/− /KRAS WT/G12D /Pdx1-Cre
(KCG, n = 12) mice, suggesting a role for the tumour suppressor p53 in the regulation of GPR55. To investigate this hypothesis, GPR55 protein expression was analysed in murine PDAC cell lines established from different transgenic mouse models. Results in Supplementary Figure 4a suggest that GPR55 protein expression is negatively associated with TP53 status, as the protein appears to be less expressed in the presence of wild type TP53 (PZR1 cells, derived from the KC model), whereas it is more expressed when TP53 is mutated (PZPR1 cells, derived from the KPC model) or deleted (PZPflR cells). Furthermore, overexpression of wild type p53 in ASPC1 cells (that harbour a TP53 mutation) reduced the expression levels of GPR55 compared to cells transfected with the empty vector (Supplementary Figure 4b) . On the other hand downregulation of p53 with two specific siRNAs strongly increased the expression levels of GPR55 in pancreatic cancer cells SW1990 that express wild type p53 ( Fig. 3b ) and in HEK293T cells (Supplementary Figure 4c) . These data indicate that wild type p53 negatively regulates GPR55 protein levels.
To gain further insight into the mechanisms of the p53-dependent regulation of GPR55, we performed luciferase assays using a plasmid containing the luciferase gene under the control of the 3′-untranslated region (3′-UTR) of GPR55 ("GPR55" in Fig. 3c) . A plasmid encoding the luciferase gene but lacking a regulatory region was used as a control ("Control" in Fig. 3c ). ASPC1 cells were cotransfected with each luciferase plasmid in combination with either an empty vector (pcDNA) or plasmids encoding wild type p53 or mutants p53 (harbouring mutations at positions 143
Ala or 175 His ). Wild type and p53 mutants were expressed to similar levels in these experimental conditions (Supplementary Figure 4d) . Results showed that the luciferase activity driven by 3′-UTR GPR55 was significantly decreased in cells expressing wild type p53 but not in cells expressing the mutant p53 (Fig. 3c ). These data demonstrate that wild type p53, but not its mutated forms, negatively affects GPR55 protein expression by specifically regulating its 3′-UTR and influencing GPR55 mRNA degradation or translation. We next investigated whether the p53-dependent regulation of 3′-UTR GPR55 occurred directly or indirectly, possibly through regulation of microRNAs (miRs). More than one algorithm predicted GPR55 as a target of several miRs belonging to the miR34 family (Supplementary Table 1) , which is known to be regulated by p53 [16] , to be downregulated in PDAC and to have a key role in PDAC progression [17] . Specifically, we observed that miR34b-3p was the only miR within this family with a binding site on 3′-UTR GPR55 as predicted by MicroCosm (Supplementary Figure 4e) , strongly suggesting that this specific miR could be involved in the p53-mediated regulation of GPR55 in PDAC cells. Consistent with this, we observed that miR34b-3p was downregulated in ASPC1 and HPAFII cells compared to the immortalised pancreatic cell line HPDE (Supplementary Figure 4f) . Reintroduction of wild type p53 in ASPC1 cells increased miR34b-3p levels (Supplementary Figure 4g) while reintroduction of miR34b-3p in HPAFII and ASPC1 cells decreased GPR55 protein expression (Fig. 3d) .
These data indicate that wild type p53 downregulates GPR55 protein expression by modulating the levels of miR34b-3p (Fig. 3e ) and suggest a mechanism by which TP53 mutations might promote cell growth through impaired regulation of miR34b-3p levels, which in turn results in increased expression of GPR55 and amplification of proliferative signals (Fig. 3e) .
Pharmacological inhibition of GPR55 reduces PDAC cell growth, cell cycle progression and MAPK signalling in vitro
Our data so far demonstrated that pancreatic cancer cell proliferation in vitro and, importantly, PDAC progression in vivo could be inhibited by genetic Gpr55 disruption. To validate the possibility of targeting GPR55 as a novel potential strategy in PDAC, we next investigated the effect of its pharmacological inhibition in vitro and in vivo. The GPR55 antagonist cannabidiol (CBD) efficiently inhibited anchorage-dependent growth of ASPC1, HPAFII, BXPC3 and PANC1 cells ( Supplementary Figure 5a-d) . Similar results were obtained using the GPR55 antagonist CID16020046 (CID) in ASPC1 and HPAFII cells (Supplementary Figure 5a and b). Treatment of HPAFII (Fig. 4a ) and PANC1 cells (Fig. 4b ) with CBD blocked cell cycle at the G1/S transition phase in a dose-dependent manner and it reduced DNA synthesis/entry in the S phase, as assessed by EdU incorporation (Fig. 4c) . Consistent with this, CBD reduced expression of cyclin D1 and activation of the tumour suppressor retinoblastoma (RB) without affecting the total levels of RB (Fig. 4d) . Inhibition of MEK/ERK and ERK-dependent pathways was also observed in cells treated with CBD (Fig. 4e) . On the other hand, no effect was detected on the total levels of any of the analysed proteins (Fig. 4e) . To investigate further the effect of CBD on different cell signalling pathways, we performed a human phospho-kinase array assay on lysates from untreated and CBD-treated HPAFII cells. Consistent with our previous data, results from the array confirmed a specific inhibition of ERK1/2 phosphorylation (25% threshold) upon treatment with CBD (Supplementary Figure 6) . Importantly, Stat5a was the only other kinase whose phosphorylation appeared to be reduced by CBD treatment (25% threshold), although further investigation of additional, independent lysates did not confirm the Stat5a phosphorylation inhibition. Overall data from the array ruled out the possibility that CBD, at the concentrations used in this study, had many off target inhibitory effects on additional signalling pathways involved in regulation of cell growth and cell cycle progression. Finally, we observed that both CBD and CID inhibited anchorage-independent growth of ASPC1 and HPAFII cells (Fig. 5a, b) .
These data indicate that pharmacological inhibition of GPR55 reduces PDAC cell cycle progression and cell growth, suggesting that GPR55 may represent a novel target to counteract PDAC progression.
Pharmacological inhibition of GPR55 potentiates the effect of gemcitabine (GEM) in vivo and in vitro
We then investigated the effect of CBD on PDAC progression in vivo either alone or in combination with GEM. KPC mice were given CBD (100 mg/kg), GEM (100 mg/ kg) or a combination of the two drugs, and survival curves were determined (Fig. 5c) . Lifespan of mice given CBD (mean 25.4 days, median 22 days) was very similar to survival of mice given GEM (mean 27.8 days, median 23.5 days). Survival of mice given the vehicle was: mean 18.6 days, median 20 days. Strikingly, a remarkable and statistically significant increase in survival was observed when CBD was used in combination with GEM, with a nearly three-fold extension of mice survival compared to mice given the vehicle (mean 52.7 vs 18.6 days, median 56 vs 20 days). To determine the mechanism(s) underlying the pronounced effect of the drug combination on PDAC growth, we next analysed tumour specimens from the four groups of mice. IHC analysis indicated that combination of the two drugs strongly reduced the percentage of proliferative cells, as assessed by Ki67 staining (Fig. 5d) . Combination of CBD and GEM reduced the number of HPAFII (Supplementary Figure 7a) and PANC1 (Supplementary Figure 7b) cells more efficiently than each compound alone, as further confirmed by analysis of combination (CI) and dose reduction (DRI) indexes [18] using CompuSyn software (Supplementary  Table 2 ).
These data indicate that combination of CBD and GEM strongly inhibits PDAC growth in vitro and in vivo. Fig. 3 p53 regulates GPR55 protein levels in PDAC. a Kaplan-Meier survival curves of KC (n = 19) and KCG (n = 12) mice. Log-rank (Mantel-Cox) test p = 0.17198, Gehan-Breslow-Wilcoxon test p = 0.9677. Representative images of H&E staining confirm presence of tumours. Scale bar: 250 µm. b Pancreatic cancer cells SW1990, expressing wild type p53, were transfected with siRNAs targeting p53 or siControl and lysed after 48 h. Representative Western blot and results from densitometry analysis are shown. Actinin was used as loading control. Data are means ± s.e.m. of n = 3 independent experiments and are expressed as fold change of normalised GPR55 levels in cells transfected with siControl. *p < 0.05. c Luciferase activity assays were performed in ASPC1 co-transfected with the indicated plasmids as specified in the Materials and Methods. Results are means ± s.e.m. of n = 5 independent experiments. *p < 0.05. d The effect of re-introduction of miR34b-3p in ASPC1 and HPAFII cells on GPR55 protein expression was assessed by Western blot. Vinculin was used as loading control. Data from densitometry analysis are expressed as fold change of normalised GPR55 levels in cells transfected with miR control and are means ± s.e.m. of n = 3 independent experiments. *p < 0.05, **p < 0.01. e Proposed model of p53/GPR55 signalling. Wild type, active p53 negatively regulates GPR55 protein expression by increasing miR34b-3p levels. The reduced GPR55 protein levels result in a weak proliferative signal. Mutated p53 is not able to regulate miR34b-3p levels and therefore GPR55 protein expression is not affected. High GPR55 protein expression results in a strong proliferative signal. Dotted arrows indicate inhibition; solid arrows indicate activation . Total levels of RB were also assessed. Tubulin was used as loading control. e Effect of CBD treatment on activation and total levels of the indicated members of the MAPK/ERK signalling pathway. Tubulin or vinculin were used as loading controls. Results from densitometry analysis are expressed as fold change of normalised results from cells incubated with vehicle ("untreated") and are means ± s.e.m. of n = 3 independent experiments apart from: pERK T202/Y204 (n = 7-9), pS6 S235/236 (n = 6), pRB
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, and RB (n = 4). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Pharmacological inhibition of GPR55 affects signalling pathways involved in acquired resistance to GEM IHC investigation revealed reduced ERK phosphorylation in tumours from mice given CBD (Fig. 6a) . A trend towards inhibition of S6 phosphorylation was also observed, although data did not reach statistical significance (Fig. 6b) . We detected increased ERK activation in tumours from mice given GEM compared to mice given the vehicle (Fig. 6a) . Increased ERK activation was previously reported upon GEM treatment and it was proposed as one of the mechanisms of acquired resistance to GEM treatment [19] . Importantly, IHC analysis of tumours from mice given a combination of CBD and GEM showed that CBD was able to counteract the effect of GEM on ERK and ultimately to reduce the GEMdependent ERK phosphorylation (Fig. 6a) . Similarly, we observed that GEM increased ERK activation in HPAFII cells and this was opposed by CBD when the two drugs were used in combination (Fig. 6c) . No effects were observed on ERK expression levels (Fig. 6c) . In the same experiments GEM induced phosphorylation of the histone variant H2AX (Fig.  6c) , a well-known marker of DNA damage.
Next, we investigated the effect of CBD on additional proposed mechanisms of GEM resistance. It was demonstrated that GEM can act by inhibiting the enzyme ribonucleotide reductase 1 (RRM1), leading to imbalance in the deoxyribonucleotides pool. Moreover, it was shown that cancer cell resistance can be associated with increased RRM1 and RRM2 expression [20, 21] . We observed that GPR55 downregulation reduced RRM1 protein expression in HPAFII cells (Fig. 7a) . Similarly, treatment with CBD reduced the levels of both RRM1 and RRM2 (Fig. 7b) . Moreover, reduced expression of RRM1 was detected in tumour specimens from KPCG compared to KPC mice (Fig.  7c) . Reduced levels of RRM1 mRNA were also observed in HPAFII cells upon treatment with CBD ( Supplementary  Figure 8a) and in KPCG compared to KPC mice (Supplementary Figure 8b ). These data led us to hypothesise that CBD could counteract potential resistance mechanisms associated with upregulation of ribonucleotide reductases. Supporting this hypothesis, we detected increased expression of RRM1 in tumours from KPC mice given GEM (Fig.  7d) . While CBD alone did not seem to affect RRM1 levels, it was able to oppose the increase of RRM1 expression induced by GEM when the two drugs were used in combination (Fig. 7d) .
Discussion
GPR55 has recently emerged as a key player in many cellular functions associated with cancer progression [11] . This role was initially suggested by the demonstration that GPR55 is the specific receptor for LPI [12, 22] whose role in cancer has been extensively described [11, [23] [24] [25] . From our original studies reporting the mitogenic properties of LPI [24, 26] , data in literature have increasingly documented the involvement of LPI in several cellular processes required for cancer progression, including cancer cell proliferation, migration and angiogenesis [22, 27, 28] . Studies also demonstrated that Ras-transformed epithelial thyroid cells and fibroblasts [24, 26] and different cancer cell lines [22, 28] are able to release LPI and increased levels of this phospholipid were found in ovarian cancer [29] and colon cancer [30] patients. Data indicating a specific requirement for GPR55 in modulation of most of the detected LPIdependent functions provided the first indication that the receptor might be involved in cancer progression. Subsequent evidence supported this conclusion, including data demonstrating that GPR55 itself is overexpressed in many cancer cells [22, 27, 31, 32] and that GPR55 mRNA levels increase in human skin, larynx and oral squamous cell carcinoma compared to healthy tissues [32] . Increased levels of GPR55 mRNA were also detected in highly aggressive breast tumours [31] and high expression of GPR55 was recently associated with basal/triple-negative breast cancer subtype [33] .
A previous study reported increased levels of GPR55 mRNA in PanIN 2/3 compared to PanIN 1b [31] . GPR55 mRNA was also detected in the PDAC cell lines Mia PaCa-2 [31] and PANC1 [34] , the latter cells also expressing the receptor at the protein level [34] . Apart from these preliminary observations, no study has investigated whether accumulation of GPR55 occurs in PDAC and whether the receptor plays a role during PDAC development and progression. In this study, we show for the first time that GPR55 accumulates in human PDAC specimens compared to corresponding ductal areas in normal pancreatic tissue and it is detectable at the protein levels in a panel of PDAC cell lines. We demonstrate that the tumour suppressor p53 negatively regulates GPR55 protein expression in a mechanism involving regulation of miR34b-3p. As miR34b-3p itself was previously reported to be downregulated in PDAC and to have a key role in PDAC progression [35] our data identify a novel p53/miR34b-3p/ GPR55 axis in this process.
We further show that downregulation and pharmacological inhibition of GPR55 reduced anchorage-dependent and independent growth of PDAC cells, consistent with data previously indicating that GPR55 is an important regulator of cancer cell proliferation [11, 22] . More importantly we report that genetic disruption of Gpr55 in KPC mice significantly reduced cancer cell proliferation in vivo, providing the first evidence that this receptor is important for pancreatic cancer proliferation in this established PDAC mouse model. Extensive in vitro characterisation further demonstrated that growth inhibition was due to inhibition of cell cycle progression without increased apoptosis and it involved regulation of MAPK signalling pathways. Indication of a direct role of GPR55 in cancer progression was previously provided by the observation that GPR55 −/− mice were more resistant to skin cancer development compared to wild type mice [32] . Similarly, and H2AX and levels of ERK were assessed by Western blotting analysis. Vinculin was used as loading control. Data from densitometry analysis are expressed as fold change of normalised results from cells incubated with vehicle ("untreated") and are means ± s.e.m. of n = 3 independent experiments. *p < 0.05 delivery of siRNA targeting GPR55 in xenografts of T98G glioma cells reduced tumour growth in vivo [31] . Inhibition of metastasis formation was detected in mice injected with human colon cancer cells and treated with pharmacological inhibitors of GPR55 [30] and in mice injected with human breast cancer cells lacking GPR55 [33] . Adding to these data, our study provides the first demonstration that disruption of Gpr55 can directly affect proliferation of the highly aggressive PDAC in the closest genetic model that is currently available to mimic the human disease and it can significantly extend the lifespan of KPC mice, providing the first evidence that targeting GPR55 can result in improvement of survival.
Although previous studies had provided preliminary indication that targeting GPR55 could potentially represent a novel therapeutic strategy in cancer [31, 32] no study so far had investigated whether pharmacological inhibition of GPR55 could directly improve survival in a model of PDAC. As we observed that GPR55 downregulation inhibited proliferation without inducing apoptosis, we decided to determine the effect of the GPR55 antagonist CBD alone or in combination with GEM, a cytotoxic drug currently used for PDAC treatment. It is worth mentioning that, although CBD has been confirmed to be a GPR55 antagonist, we could not completely rule out the possibility of additional effects of the drug, independent of GPR55 inhibition. However, the observation that similar data were obtained in vitro upon treatment with CBD or with the specific GPR55 antagonist CID as well as upon downregulation of GPR55 strongly supported the conclusion that the reduced cell growth/cell cycle progression detected in PDAC cells upon treatment with CBD was mainly due to inhibition of GPR55. Furthermore, results from the phospho-kinase array assay indicated that CBD did not inhibit activation of many signalling pathways, ruling out the possibility that the compound, at the concentrations used in our study, had many off target effects. Finally, we decided to use CBD in the in vivo experiments as this drug is already approved for medical use therefore results from our study could have an immediate potential translational value. Here we report that KPC mice given a combination of CBD and GEM survived nearly three times longer compared to KPC mice given the vehicle (mean 52.7 vs 18.6 days, median 56 vs 20 days) and also longer than mice given GEM alone (mean 52.7 vs 27.8 days, median 56 vs 23.5). Our data further indicate that the remarkable increase in survival is likely due to the ability of the drugs combination to inhibit cancer cell proliferation and to overcome mechanisms involved in development of resistance to GEM treatment. To the best of our knowledge our study is the first demonstration that inhibition of GPR55 not only reduces cancer progression in a well-established transgenic model but it also represents a therapeutically valid strategy. In this respect, this study provides the first validation of GPR55 as a novel target for cancer treatment likely to be able to improve patients' outcome significantly.
The importance and clinical relevance of these results are further highlighted by the observation that they were obtained in a model of PDAC, one of the deadliest cancer types and in urgent need of novel treatment options. The very few therapeutic options currently available for advanced PDAC solely increase survival by few months leaving the five years survival rate at a mere 5%. Development of drug resistance is one of the main reasons for such an abysmal prognosis. Our demonstration that combination of CBD and GEM can oppose mechanisms associated with drug resistance and increase survival of KPC mice is very important considering that both drugs are already approved for medical use and therefore this combination can be quickly tested in clinical trials.
In conclusion, our study identified GPR55 as a novel critical mediator of PDAC development and progression. The demonstration that GPR55 is negatively regulated by p53 and it controls cell cycle progression and growth of pancreatic cancer cells provides novel information into the mechanisms by which TP53 mutations can lead to PDAC development. Moreover, our study provides the first evidence that GPR55 is a therapeutically valid target whose inhibition, in particular in combination with GEM, results in improved survival in the transgenic model closest to the human disease currently available. These results represent a huge step forward towards the identification of a novel treatment regime that could highly benefit PDAC patients.
Materials and methods

Mouse strains
All animal experiments were conducted in compliance with institutional and national guidelines. −/− mice and KPC control mice were maintained on a GPR55 background. Mice were ear-marked and specimen-genotyped via DNA extraction and PCR (out sourced to Transnetyx Inc.). KPC mice used for drug treatments were maintained on a mixed C57BL/6,129Sv1 background. KPC mice were treated with CBD (GW Pharmaceuticals, 100 mg/kg), GEM (100 mg/kg) and with a combination of the two treatments. Mice enrolment was based on tumour size, measured by palpation. Specifically, mice underwent palpation every 24 h once they reached 80 days of age (predicted age when tumours should start to develop). Mice were assigned to the four arms (vehicle, CBD, GEM, CBD + GEM) by simple randomisation using a shuffled deck of cards as described [36] . Vehicle and CBD were administered by daily intraperitoneal injection while GEM was administered by intraperitoneal injection every 3 days. Mice were checked daily and left until death or culled when pre-assigned end points were reached. The preassigned end points included mice displaying one of the following: development of abdominal ascites, severe cachexia, significant weight loss (approaching 20% of initial weight), extreme weakness, inactivity, discomfort, or pain. No major side/adverse effects and no weight loss were observed in mice treated with CBD.
Immunohistochemistry (IHC)
Mouse pancreatic tissues were placed in 10% neutralbuffered formalin immediately after sacrifice and incubated for at least 24 h. After embedding and sectioning procedures, tissues were stained with Hematoxylin and Eosin (H&E) to confirm the presence of tumours. Antibody staining was performed on 5 μm-thick sections with the following antibodies and dilutions: GPR55 (1 M urea buffer; dilution 1:100, 1:800; Novus Biologicals); pERK T202/Y204 (pH 6.0; dilution 1:75; Cell Signalling Technology); pS6 S235/236 (pH 9.0; dilution 1:100; Cell Signalling Technology); RRM1 (pH 6.0; dilution 1:250; Abcam); Ki67 (pH 6.0; dilution 1:75; eBioscience). Representative images of antibody optimisation are shown in Supplementary Table 3 . IHC slides were scored independently by two pathologists (RL and MP) blind to molecular data. The normal pancreatic tissue presented in Fig. 1a was obtained from a patient without any findings of pancreatic cancer.
Tissue microarray (TMA)
Archived formalin-fixed, paraffin-embedded blocks from 54 patients diagnosed with primary PDAC were retrieved at the "Regina Elena" National Cancer Institute (Rome, Italy).
TMA were constructed by removing 2 mm diameter cores of histologically confirmed tumour areas. TMA sections were then incubated with anti-GPR55 rabbit polyclonal antibody (dilution 1:100, incubation overnight, Novus Biologicals) after antigen retrieval by microwave treatment at 750 W for 10 min in 1 M urea buffer. Anti-rabbit EnVision kit (K4003, Dako, Glostrup, Denmark) was used for signal amplification. In control sections, the primary antibody was replaced with isotype-matched immunoglobulins. The expression of markers was quantified as percent of immunoreactive cells.
Statistics
All sample sizes were chosen based upon prior studies performed in our laboratories and appropriate power calculations performed by expert biostatisticians of the School of Public Health at Curtin University. Unless otherwise specified Student's t-test (one-sided) was used to determine statistical significance. In each case *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Fig. 7 Effect of GPR55 disruption and pharmacological treatment on ribonucleotide reductase levels. a HPAFII cells were transfected with the indicated siRNAs or transfection reagent ("untreated") and lysed after 72 h. Levels of RRM1 were assessed by Western blotting. Data from densitometry analysis are expressed as fold change of normalised results from cells transfected with siControl and are means ± s.e.m. of n = 3 independent experiments. *p < 0.05. b HPAFII cells were treated with the indicated concentrations of CBD for 24 h or 72 h and levels of RRM1 and RRM2 were assessed by Western blotting. Tubulin or vinculin were used as loading controls. Data from densitometry analysis are expressed as fold change of normalised results from cells incubated with vehicle ("untreated") and are means ± s.e.m. of n = 3 independent experiments apart from RRM2 at 24 h (n = 4). *p < 0.05, **p < 0.01. c, d Representative images of PDAC specimens from KPC and KPCG mice (c) or KPC mice given CBD and GEM (d) stained with anti-RRM1 antibody. Scale bar: 50 µm. Graph indicates the percentage of PDAC cells showing positive staining
